We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

TWAV:NASDAQTaoWeave, Inc. Analysis

Data as of 2026-05-06 - not real-time

$1.88

Latest Price

8/10Risk

Risk Level: High

Executive Summary

TaoWeave, Inc. (TWAV) is trading at $1.88, comfortably above its 20‑day ($1.71) and 50‑day ($1.48) simple moving averages but still below the 200‑day SMA of $2.23, indicating short‑term momentum with a longer‑term downtrend. The RSI sits at 62, suggesting the stock is approaching overbought territory, while the MACD histogram is slightly negative and the signal line is flagged as bearish, hinting at potential downside pressure. Volatility is extreme at over 110% on a 30‑day basis and the beta of 3.29 underscores a price that swings dramatically relative to the market. The company’s fundamentals are weak: operating margins are –126%, profit margins –261%, and both operating and free cash flow are deeply negative, with a massive –87% max drawdown from its peak. Despite a price‑to‑book ratio of 0.89 (price below book value) and a modest price‑to‑sales of 2.57, the lack of earnings (PE = 0) and a cash balance of $2.26 M against a market cap of $6.26 M provide limited cushion. The firm operates in the high‑risk crypto‑adjacent asset‑management niche, with regulatory and market‑structure uncertainties adding to its risk profile. Given the stable but low trading volume and a market cap under $10 M, liquidity is constrained, and any adverse news could exacerbate price swings. Overall, the stock exhibits a blend of technical support near $1.45 and resistance near $1.97, but the confluence of negative cash flows, high volatility, and regulatory exposure makes the upside speculative.
Investors should view TWAV as a high‑risk, speculative play where the current price may not fully reflect the underlying business challenges. The lack of a dividend, combined with a negative ROE of –115% and a severe cash‑burn trajectory, suggests limited near‑term upside unless the Bittensor ecosystem experiences a breakout. While the price is below book value, the company’s operational deficits and exposure to crypto‑regulation outweigh any perceived valuation discount, positioning the stock as overvalued relative to its risk and earnings prospects.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Price above short‑term SMAs indicating residual momentum
  • RSI near overbought levels
  • Bearish MACD signal suggesting potential pullback

Medium Term

1–3 years
Cautious
Model confidence: 7/10

Key Factors

  • Sustained negative operating and free cash flow
  • Extreme volatility and high beta amplifying downside risk
  • Regulatory uncertainty surrounding crypto‑related assets

Long Term

> 3 years
Cautious
Model confidence: 8/10

Key Factors

  • Persistent lack of profitability and negative ROE
  • High max drawdown of 87% indicating historical price weakness
  • Limited liquidity and small market cap restricting investor participation

Key Metrics & Analysis

Financial Health

Revenue Growth10.50%
Profit Margin-260.77%
ROE-115.17%
ROA-27.44%
P/B Ratio0.9
Op. Cash Flow$-3015000
Free Cash Flow$-7421250
Industry P/E16.6

Technical Analysis

TrendNeutral
RSI62.1
Support$1.45
Resistance$1.97
MA 20$1.71
MA 50$1.48
MA 200$2.23
MACDBearish
VolumeStable
Fear & Greed Index90.38

Valuation

GradeOvervalued
TypeValue

Risk Assessment

Beta3.29
Volatility110.65%
Sector RiskHigh
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.